Table 2.
Demographic characteristics of CUAs.
| Study characteristic | No. Studies (%) | Mean CEA registry quality score (range) |
|---|---|---|
| Subspecialty | ||
| Otology | 19 (31.1) | 3.8 (1.5–6.0) |
| Endocrine surgery | 12 (19.7) | 4.2 (3.5–5.5) |
| Sleep medicine/surgery | 11 (18.0) | 4.2 (2.5–6.0) |
| Head and neck surgery | 8 (13.0) | 3.4 (2.5–5.0) |
| Pediatric otolaryngology | 5 (8.2) | 4.3 (3.0–5.5) |
| Allergy | 4 (6.6) | 4.5 (3.5–6.0) |
| Rhinology | 2 (3.3) | 4.5 (4.0–5.0) |
| Journal (2011 impact factor) | ||
| Laryngoscope (1.752) | 6 (9.8) | 3.3 (1.5–4.5) |
| Arch of Otolaryngology Head Neck Surg (1.63) | 4 (6.6) | 4.1 (1.5–5.0) |
| Ear Hearing (2.578) | 3 (4.9) | 4.5 (3.0–6.0) |
| Sleep (5.051) | 3 (4.9) | 4.2 (2.5–5.0) |
| Value Health (2.191) | 3 (4.9) | 5.0 (4.0–6.0) |
| Others | 36 (59) | 4.1 (1.5–6.0) |
| Total No. of Journals | 41 | 4.0 (1.5–6.0) |
| Year of publication | ||
| 1976–1991 | 1 (1.6) | 3.0 |
| 1992–1995 | 4 (6.6) | 2.1 (1.5–3.0) |
| 1996–1999 | 4 (6.6) | 3.9 (2–5.5) |
| 2000–2003 | 10 (16.4) | 3.9 (1.5–5.5) |
| 2004–2007 | 14 (22.9) | 4.0 (3.0–6.0) |
| 2008–2011 | 28 (45.9) | 4.4 (2.5–6.0) |
| Country of analysis | ||
| United States | 32 (52.4) | 3.9 (1.5–6.0) |
| United Kingdom | 8 (13.1) | 4.7 (1.5–6.0) |
| Canada | 5 (8.2) | 4.1 (2.5–5.5) |
| Australia | 3 (4.9) | 3.3 (3.0–4.0) |
| Germany | 3 (4.9) | 4.2 (4.0–4.5) |
| France | 2 (3.3) | 4.5 (3.5–5.5) |
| Netherlands | 2 (3.3) | 3.5 (2.0–5.0) |
| New Zealand | 1 (1.6) | 4.0 |
| Austria | 1 (1.6) | 3.5 |
| China | 1 (1.6) | 3.0 |
| Finland | 1 (1.6) | 3.0 |
| Belgium | 1 (1.6) | 5.0 |
| Taiwan | 1 (1.6) | 5.0 |
| Funding source | ||
| Government | 17 (27.9) | 4.1 (1.5–6.0) |
| Pharmaceutical or device | 14 (22.9) | 3.8 (1.5–5.5) |
| Could not be determined | 29 (47.5) | 3.9 (1.5–6.0) |
| Foundation | 6 (9.8) | 4.3 (3.0–5.5) |
| Healthcare organization | 3 (4.9) | 3.5 (1.5–4.5) |
| Perspective of study | ||
| Healthcare payer | 43 (70.5) | 3.9 (1.5–6.0) |
| Societal | 17 (27.9) | 4.4 (3.0–5.5) |
| Could not be determined | 1 (1.6) | 1.5 |
| Intervention type | ||
| Primary | 2 (3.3) | 4.8 (4.0–5.5) |
| Secondary | 13 (21.3) | 3.8 (2.0–6.0) |
| Tertiary | 46 (75.4) | 4.0 (1.5–6.0) |
| Authors affiliation | ||
| Academic | 60 (98.4) | 4.0 (1.5–6.0) |
| Consultant | 7 (11.5) | 4.4 (3.5–5.0) |
| Government | 1 (1.6) | 3.0 |
| Intervention assessed | ||
| Device | 29 (47.5) | 3.8 (1.5–6.0) |
| Diagnostic | 6 (9.8) | 4.0 (3.0–5.0) |
| Screening | 6 (9.8) | 3.4 (2.0–5.0) |
| Health education | 1 (1.6) | 4.0 |
| Medical procedure | 9 (14.7) | 4.1 (3.0–5.0) |
| Pharmaceutical | 18 (29.5) | 4.6 (3.5–6.0) |
| Surgical | 12 (19.7) | 3.9 (2.5–5.5) |
| Immunization | 2 (3.3) | 5.0 (4.5–5.5) |
| Care delivery | 2 (3.3) | 3.3 (3.0–3.5) |